Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026.
Dr. Vink, MD, MBA, has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. Dr. Vink previously served as EVP and COO of Cubist Pharmaceuticals, overseeing global commercial and technical operations until its $9.5 billion acquisition by Merck in 2015.
In a statement, Richard Muruvé, CEO of Arch, commented, “We are happy to have Patrick rejoin the board as our new chairman during this exciting stage of development for Arch. Patrick’s experience in the pharma industry, combined with his network within the financial markets, will be very helpful to Arch as we advance our acute kidney injury Phase 2 trials and our chronic kidney disease program.”
